Mechanisms of estrogen effects on the endothelium: An overview

Canadian Journal of Cardiology

Volumn 30, Issue 7, 2014, Pages 705-712

  Chakrabarti, Subhadeep ^a   Morton, Jude S ^a   Davidge, Sandra T ^a  

^a MAZANKOWSKI ALBERTA HEART INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ENDOTHELIAL NITRIC OXIDE SYNTHASE; ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR AGONIST; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; G PROTEIN COUPLED RECEPTOR 30; HORMONE RECEPTOR STIMULATING AGENT; NITRIC OXIDE; PROSTACYCLIN; PROSTAGLANDIN E2; SELECTIVE ESTROGEN RECEPTOR MODULATOR; UNCLASSIFIED DRUG;

AGE; AGING; ANTIDIABETIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; BIOAVAILABILITY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR EFFECT; CLINICAL TRIAL (TOPIC); DIABETES MELLITUS; ESTROGEN ACTIVITY; HUMAN; MODULATION; NONHUMAN; POSTMENOPAUSE; PREGNANCY; PREMENOPAUSE; REVIEW; SIGNAL TRANSDUCTION; SUPPLEMENTATION; TRANSCRIPTION INITIATION; VASCULAR ENDOTHELIUM; VASCULAR RESISTANCE; VASODILATATION;

CARDIOVASCULAR DISEASES; ENDOTHELIUM, VASCULAR; ESTROGENS; FEMALE; HUMANS; MALE; PREGNANCY; PROGNOSIS; RECEPTORS, ESTROGEN; VASODILATION;

EID: 84903168409     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cjca.2013.08.006     Document Type: Review

References (88)

1. Rao R.M., Yang L., Garcia-Cardena G., Luscinskas F.W. Endothelial-dependent mechanisms of leukocyte recruitment to the vascular wall. Circ Res 2007, 101:234-247.
2. Regitz-Zagrosek V. Therapeutic implications of the gender-specific aspects of cardiovascular disease. Nat Rev Drug Discov 2006, 5:425-438.
3. Stork S., van der Schouw Y.T., Grobbee D.E., Bots M.L. Estrogen, inflammation and cardiovascular risk in women: a critical appraisal. Trends Endocrinol Metab 2004, 15:66-72.
4. Kim J.K., Levin E.R. Estrogen signaling in the cardiovascular system. Nucl Recept Signal 2006, 4:e013.
5. Strehlow K., Rotter S., Wassmann S., et al. Modulation of antioxidant enzyme expression and function by estrogen. Circ Res 2003, 93:170-177.
6. Chakrabarti S., Lekontseva O., Davidge S.T. Estrogen is a modulator of vascular inflammation. IUBMB Life 2008, 60:376-382.
7. Zhang Y., Davidge S.T. Estrogen replacement increases coronary artery distensibility in ovariectomized rats. Can J Physiol Pharmacol 1999, 77:75-78.
8. Arnal J.F., Scarabin P.Y., Tremollieres F., Laurell H., Gourdy P. Estrogens in vascular biology and disease: where do we stand today?. Curr Opin Lipidol 2007, 18:554-560.
9. Grodstein F., Stampfer M.J., Manson J.E., et al. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. NEngl J Med 1996, 335:453-461.
10. Hsia J., Langer R.D., Manson J.E., et al. Conjugated equine estrogens and coronary heart disease: the women's health initiative. Arch Intern Med 2006, 166:357-365.
11. Salpeter S.R., Walsh J.M., Ormiston T.M., Greyber E., Buckley N.S., Salpeter E.E. Meta-analysis: effect of hormone-replacement therapy on components of the metabolic syndrome in postmenopausal women. Diabetes Obes Metab 2006, 8:538-554.
12. Hodis H.N., Mack W.J. A"window of opportunity:" the reduction of coronary heart disease and total mortality with menopausal therapies is age- and time-dependent. Brain Res 2011, 1379:244-252.
13. Walter P., Green S., Greene G., et al. Cloning of the human estrogen receptor cdna. Proc Natl Acad Sci U S A 1985, 82:7889-7893.
14. Kuiper G.G., Enmark E., Pelto-Huikko M., Nilsson S., Gustafsson J.A. Cloning of a novel receptor expressed in rat prostate and ovary. Proc Natl Acad Sci U S A 1996, 93:5925-5930.
15. Luksha L., Kublickiene K. The role of estrogen receptor subtypes for vascular maintenance. Gynecol Endocrinol 2009, 25:82-95.
16. Chakrabarti S., Davidge S.T. High glucose-induced oxidative stress alters estrogen effects on ERalpha and ERbeta in human endothelial cells: reversal by AMPK activator. JSteroid Biochem Mol Biol 2009, 117:99-106.
17. Tamir S., Izrael S., Vaya J. The effect of oxidative stress on eralpha and erbeta expression. JSteroid Biochem Mol Biol 2002, 81:327-332.
18. Haas E., Meyer M.R., Schurr U., et al. Differential effects of 17beta-estradiol on function and expression of estrogen receptor alpha, estrogen receptor beta, and GPR30 in arteries and veins of patients with atherosclerosis. Hypertension 2007, 49:1358-1363.
19. Russell K.S., Haynes M.P., Sinha D., Clerisme E., Bender J.R. Human vascular endothelial cells contain membrane binding sites for estradiol, which mediate rapid intracellular signaling. Proc Natl Acad Sci U S A 2000, 97:5930-5935.
20. Smiley D.A., Khalil R.A. Estrogenic compounds, estrogen receptors and vascular cell signaling in the aging blood vessels. Curr Med Chem 2009, 16:1863-1887.
21. Lombardi G., Zarrilli S., Colao A., et al. Estrogens and health in males. Mol Cell Endocrinol 2001, 178:51-55.
22. Shih H.C., Lin C.L., Wu S.C., Kwan A.L., Hong Y.R., Howng S.L. Upregulation of estrogen receptor alpha and mediation of 17beta-estradiol vasoprotective effects via estrogen receptor alpha in basilar arteries in rats after experimental subarachnoid hemorrhage. JNeurosurg 2008, 109:92-99.
23. Douglas G., Cruz M.N., Poston L., Gustafsson J.A., Kublickiene K. Functional characterization and sex differences in small mesenteric arteries of the estrogen receptor-beta knockout mouse. Am J Physiol Regul Integr Comp Physiol 2008, 294:R112-R120.
24. Lahm T., Crisostomo P.R., Markel T.A., et al. Selective estrogen receptor-alpha and estrogen receptor-beta agonists rapidly decrease pulmonary artery vasoconstriction by a nitric oxide-dependent mechanism. Am J Physiol Regul Integr Comp Physiol 2008, 295:R1486-R1493.
25. Villablanca A.C., Tetali S., Altman R., Ng K.F., Rutledge J.C. Testosterone-derived estradiol production by male endothelium is robust and dependent on p450 aromatase via estrogen receptor alpha. Springerplus 2013, 2:214.
26. Carmeci C., Thompson D.A., Ring H.Z., Francke U., Weigel R.J. Identification of a gene (GPR30) with homology to the g-protein-coupled receptor superfamily associated with estrogen receptor expression in breast cancer. Genomics 1997, 45:607-617.
27. Revankar C.M., Mitchell H.D., Field A.S., et al. Synthetic estrogen derivatives demonstrate the functionality of intracellular GPR30. ACS Chem Biol 2007, 2:536-544.
28. Barton M. Position paper: the membrane estrogen receptor GPER - clues and questions. Steroids 2012, 77:935-942.
29. Batenburg W.W., Jansen P.M., van den Bogaerdt A.J., J Danser A.H. Angiotensin II-aldosterone interaction in human coronary microarteries involves GPR30, EGFR, and endothelial NO synthase. Cardiovasc Res 2012, 94:136-143.
30. Lindsey S.H., Carver K.A., Prossnitz E.R., Chappell M.C. Vasodilation in response to the GPR30 agonist G-1 is not different from estradiol in the mren2.Lewis female rat. JCardiovasc Pharmacol 2011, 57:598-603.
31. Broughton B.R., Miller A.A., Sobey C.G. Endothelium-dependent relaxation by G protein-coupled receptor 30 agonists in rat carotid arteries. Am J Physiol Heart Circ Physiol 2010, 298:H1055-H1061.
32. Lindsey S.H., da Silva A.S., Silva M.S., Chappell M.C. Reduced vasorelaxation to estradiol and G-1 in aged female and adult male rats is associated with GPR30 downregulation. Am J Physiol Endocrinol Metab 2013, 305:E113-E118.
33. Chakrabarti S., Davidge S.T. G-protein coupled receptor 30 (GPR30): a novel regulator of endothelial inflammation. PLoS One 2012, 7:e52357.
34. Evans M.J., Harris H.A., Miller C.P., Karathanasis S.K., Adelman S.J. Estrogen receptors alpha and beta have similar activities in multiple endothelial cell pathways. Endocrinology 2002, 143:3785-3795.
35. Li L., Haynes M.P., Bender J.R. Plasma membrane localization and function of the estrogen receptor alpha variant (er46) in human endothelial cells. Proc Natl Acad Sci U S A 2003, 100:4807-4812.
36. Szego C.M., Davis J.S. Inhibition of estrogen-induced elevation of cyclic 3',5'-adenosine monophosphate in rat uterus. I. By beta-adrenergic receptor-blocking drugs. Mol Pharmacol 1969, 5:470-480.
37. Deschamps A.M., Murphy E., Sun J. Estrogen receptor activation and cardioprotection in ischemia reperfusion injury. Trends Cardiovasc Med 2010, 20:73-78.
38. Kim K.H., Bender J.R. Rapid, estrogen receptor-mediated signaling: why is the endothelium so special?. Sci STKE 2005, 2005:pe28.
39. Watson C.S., Alyea R.A., Jeng Y.J., Kochukov M.Y. Nongenomic actions of low concentration estrogens and xenoestrogens on multiple tissues. Mol Cell Endocrinol 2007, 274:1-7.
40. Wu Q., Chambliss K., Umetani M., Mineo C., Shaul P.W. Non-nuclear estrogen receptor signaling in the endothelium. JBiol Chem 2011, 286:14737-14743.
41. Chambliss K.L., Yuhanna I.S., Mineo C., et al. Estrogen receptor alpha and endothelial nitric oxide synthase are organized into a functional signaling module in caveolae. Circ Res 2000, 87:E44-E52.
42. Caulin-Glaser T., Garcia-Cardena G., Sarrel P., Sessa W.C., Bender J.R. 17 beta-estradiol regulation of human endothelial cell basal nitric oxide release, independent of cytosolic Ca2+ mobilization. Circ Res 1997, 81:885-892.
43. Orshal J.M., Khalil R.A. Gender, sex hormones, and vascular tone. Am J Physiol Regul Integr Comp Physiol 2004, 286:R233-R249.
44. Dan P., Cheung J.C., Scriven D.R., Moore E.D. Epitope-dependent localization of estrogen receptor-alpha, but not -beta, in en face arterial endothelium. Am J Physiol Heart Circ Physiol 2003, 284:H1295-H1306.
45. Temple J.L., Wray S. Bovine serum albumin-estrogen compounds differentially alter gonadotropin-releasing hormone-1 neuronal activity. Endocrinology 2005, 146:558-563.
46. Chambliss K.L., Wu Q., Oltmann S., et al. Non-nuclear estrogen receptor alpha signaling promotes cardiovascular protection but not uterine or breast cancer growth in mice. JClin Invest 2010, 120:2319-2330.
47. Madeo A., Maggiolini M. Nuclear alternate estrogen receptor GPR30 mediates 17beta-estradiol-induced gene expression and migration in breast cancer-associated fibroblasts. Cancer Res 2010, 70:6036-6046.
48. Li Z.L., Liu J.C., Liu S.B., Li X.Q., Yi D.H., Zhao M.G. Improvement of vascular function by acute and chronic treatment with the GPR30 agonist G-1 in experimental diabetes mellitus. PLoS One 2012, 7:e38787.
49. Bkaily G., Choufani S., Hassan G., El-Bizri N., Jacques D., D'Orleans-Juste P. Presence of functional endothelin-1 receptors in nuclear membranes of human aortic vascular smooth muscle cells. JCardiovasc Pharmacol 2000, 36:S414-S417.
50. Ding Q., Gros R., Limbird L.E., Chorazyczewski J., Feldman R.D. Estradiol-mediated ERK phosphorylation and apoptosis in vascular smooth muscle cells requires GPR 30. Am J Physiol Cell Physiol 2009, 297:C1178-C1187.
51. Tang H.Y., Lin H.Y., Zhang S., Davis F.B., Davis P.J. Thyroid hormone causes mitogen-activated protein kinase-dependent phosphorylation of the nuclear estrogen receptor. Endocrinology 2004, 145:3265-3272.
52. Knowlton A.A., Lee A.R. Estrogen and the cardiovascular system. Pharmacol Ther 2012, 135:54-70.
53. Haynes M.P., Li L., Sinha D., et al. Src kinase mediates phosphatidylinositol 3-kinase/Akt-dependent rapid endothelial nitric-oxide synthase activation by estrogen. JBiol Chem 2003, 278:2118-2123.
54. Rosenfeld C.R., Chen C., Roy T., Liu X. Estrogen selectively up-regulates enos and nnos in reproductive arteries by transcriptional mechanisms. JSoc Gynecol Investig 2003, 10:205-215.
55. Tan E., Gurjar M.V., Sharma R.V., Bhalla R.C. Estrogen receptor-alpha gene transfer into bovine aortic endothelial cells induces enos gene expression and inhibits cell migration. Cardiovasc Res 1999, 43:788-797.
56. Lekontseva O., Chakrabarti S., Jiang Y., Cheung C.C., Davidge S.T. Role of neuronal nitric-oxide synthase in estrogen-induced relaxation in rat resistance arteries. JPharmacol Exp Ther 2011, 339:367-375.
57. Miller A.A., Drummond G.R., Mast A.E., Schmidt H.H., Sobey C.G. Effect of gender on NADPH-oxidase activity, expression, and function in the cerebral circulation: role of estrogen. Stroke 2007, 38:2142-2149.
58. Chakrabarti S., Lekontseva O., Peters A., Davidge S.T. 17beta-estradiol induces protein s-nitrosylation in the endothelium. Cardiovasc Res 2010, 85:796-805.
59. Zhang H.H., Feng L., Livnat I., et al. Estradiol-17beta stimulates specific receptor and endogenous nitric oxide-dependent dynamic endothelial protein s-nitrosylation: analysis of endothelial nitrosyl-proteome. Endocrinology 2010, 151:3874-3887.
60. Jobe S.O., Ramadoss J., Wargin A.J., Magness R.R. Estradiol-17beta and its cytochrome p450- and catechol-o-methyltransferase-derived metabolites selectively stimulate production of prostacyclin in uterine artery endothelial cells: role of estrogen receptor-alpha versus estrogen receptor-beta. Hypertension 2013, 61:509-518.
61. Pedram A., Razandi M., Aitkenhead M., Hughes C.C., Levin E.R. Integration of the non-genomic and genomic actions of estrogen. Membrane-initiated signaling by steroid to transcription and cell biology. JBiol Chem 2002, 277:50768-50775.
62. Zhou K., Gao Q., Zheng S., et al. 17beta-estradiol induces vasorelaxation by stimulating endothelial hydrogen sulfide release. Mol Hum Reprod 2013, 19:169-176.
63. Chambliss K.L., Shaul P.W. Estrogen modulation of endothelial nitric oxide synthase. Endocr Rev 2002, 23:665-686.
64. Gray G.A., Sharif I., Webb D.J., Seckl J.R. Oestrogen and the cardiovascular system: the good, the bad and the puzzling. Trends Pharmacol Sci 2001, 22:152-156.
65. Harris H.A. Estrogen receptor-beta: recent lessons from invivo studies. Mol Endocrinol 2007, 21:1-13.
66. Knowlton A.A. Estrogen and cardiovascular disease: aging and estrogen loss at the heart of the matter?. Future Cardiol 2012, 8:9-12.
67. Miller A.P., Xing D., Feng W., Fintel M., Chen Y.F., Oparil S. Aged rats lose vasoprotective and anti-inflammatory actions of estrogen in injured arteries. Menopause 2007, 14:251-260.
68. Novella S., Dantas A.P., Segarra G., et al. Gathering of aging and estrogen withdrawal in vascular dysfunction of senescent accelerated mice. Exp Gerontol 2010, 45:868-874.
69. Bolego C., Cignarella A., Sanvito P., et al. The acute estrogenic dilation of rat aorta is mediated solely by selective estrogen receptor-alpha agonists and is abolished by estrogen deprivation. JPharmacol Exp Ther 2005, 313:1203-1208.
70. Novella S., Heras M., Hermenegildo C., Dantas A.P. Effects of estrogen on vascular inflammation: a matter of timing. Arterioscler Thromb Vasc Biol 2012, 32:2035-2042.
71. Schierbeck L.L., Rejnmark L., Tofteng C.L., et al. Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial. BMJ 2012, 345:e6409.
72. Pastore M.B., Jobe S.O., Ramadoss J., Magness R.R. Estrogen receptor-alpha and estrogen receptor-beta in the uterine vascular endothelium during pregnancy: functional implications for regulating uterine blood flow. Semin Reprod Med 2012, 30:46-61.
73. Perez-Sepulveda A., Torres M.J., Valenzuela F.J., et al. Low 2-methoxyestradiol levels at the first trimester of pregnancy are associated with the development of pre-eclampsia. Prenat Diagn 2012, 32:1053-1058.
74. Kanaya A.M., Grady D., Barrett-Connor E. Explaining the sex difference in coronary heart disease mortality among patients with type 2 diabetes mellitus: a meta-analysis. Arch Intern Med 2002, 162:1737-1745.
75. Kannel W.B., Wilson P.W. Risk factors that attenuate the female coronary disease advantage. Arch Intern Med 1995, 155:57-61.
76. Somjen D., Paller C.J., Gayer B., Kohen F., Knoll E., Stern N. High glucose blocks the effects of estradiol on human vascular cell growth: differential interaction with estradiol and raloxifene. JSteroid Biochem Mol Biol 2004, 88:101-110.
77. Meyer M.R., Clegg D.J., Prossnitz E.R., Barton M. Obesity, insulin resistance and diabetes: sex differences and role of oestrogen receptors. Acta Physiol (Oxf) 2011, 203:259-269.
78. Tanaka N., Yonekura H., Yamagishi S., Fujimori H., Yamamoto Y., Yamamoto H. The receptor for advanced glycation end products is induced by the glycation products themselves and tumor necrosis factor-alpha through nuclear factor-kappa b, and by 17beta-estradiol through sp-1 in human vascular endothelial cells. JBiol Chem 2000, 275:25781-25790.
79. Mukherjee T.K., Reynolds P.R., Hoidal J.R. Differential effect of estrogen receptor alpha and beta agonists on the receptor for advanced glycation end product expression in human microvascular endothelial cells. Biochim Biophys Acta 2005, 1745:300-309.
80. do Nascimento G.R., Barros Y.V., Wells A.K., Khalil R.A. Research into specific modulators of vascular sex hormone receptors in the management of postmenopausal cardiovascular disease. Curr Hypertens Rev 2009, 5:283-306.
81. Khalil R.A. Potential approaches to enhance the effects of estrogen on senescent blood vessels and postmenopausal cardiovascular disease. Cardiovasc Hematol Agents Med Chem 2010, 8:29-46.
82. Serock M.R., Wells A.K., Khalil R.A. Modulators of vascular sex hormone receptors and their effects in estrogen-deficiency states associated with menopause. Recent Pat Cardiovasc Drug Discov 2008, 3:165-186.
83. Duvernoy C.S., Yeo A.A., Wong M., Cox D.A., Kim H.M. Antiplatelet therapy use and the risk of venous thromboembolic events in the Raloxifene Use for The Heart (RUTH) trial. JWomens Health (Larchmt) 2010, 19:1459-1465.
84. Widder J., Pelzer T., von Poser-Klein C., et al. Improvement of endothelial dysfunction by selective estrogen receptor-alpha stimulation in ovariectomized SHR. Hypertension 2003, 42:991-996.
85. Bolego C., Vegeto E., Pinna C., Maggi A., Cignarella A. Selective agonists of estrogen receptor isoforms: new perspectives for cardiovascular disease. Arterioscler Thromb Vasc Biol 2006, 26:2192-2199.
86. Sun J., Ma X., Chen Y.X., et al. Attenuation of atherogenesis via the anti-inflammatory effects of the selective estrogen receptor beta modulator 8B-VE2. JCardiovasc Pharmacol 2011, 58:399-405.
87. Prossnitz E.R., Barton M. The G-protein-coupled estrogen receptor GPER in health and disease. Nat Rev Endocrinol 2011, 7:715-726.
88. Kumar R., Balhuizen A., Amisten S., Lundquist I., Salehi A. Insulinotropic and antidiabetic effects of 17β-estradiol and the GPR30 agonist G-1 on human pancreatic islets. Endocrinology 2011, 152:2568-2579.